10x Genomics Inc.

7.51
-0.52 (-6.48%)
At close: Apr 17, 2025, 3:59 PM
7.68
2.24%
After-hours: Apr 17, 2025, 07:56 PM EDT

10x Genomics Statistics

Share Statistics

10x Genomics has 123.43M shares outstanding. The number of shares has increased by 2.17% in one year.

Shares Outstanding 123.43M
Shares Change (YoY) 2.17%
Shares Change (QoQ) 1.03%
Owned by Institutions (%) 87.07%
Shares Floating 114.94M
Failed to Deliver (FTD) Shares 133
FTD / Avg. Volume < 0.01%

Short Selling Information

The latest short interest is 12.06M, so 9.86% of the outstanding shares have been sold short.

Short Interest 12.06M
Short % of Shares Out 9.86%
Short % of Float 12.87%
Short Ratio (days to cover) 4.1

Valuation Ratios

The PE ratio is -9.47 and the forward PE ratio is -6.5. 10x Genomics's PEG ratio is 0.31.

PE Ratio -9.47
Forward PE -6.5
PS Ratio 2.83
Forward PS 1.1
PB Ratio 2.44
P/FCF Ratio -301.92
PEG Ratio 0.31
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for 10x Genomics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 4.97, with a Debt / Equity ratio of 0.12.

Current Ratio 4.97
Quick Ratio 4.26
Debt / Equity 0.12
Debt / EBITDA -0.62
Debt / FCF -14.42
Interest Coverage -48639.75

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $467.68K
Profits Per Employee $-139.84K
Employee Count 1,306
Asset Turnover 0.66
Inventory Turnover 2.36

Taxes

Income Tax 4.93M
Effective Tax Rate -2.77%

Stock Price Statistics

The stock price has increased by -73.96% in the last 52 weeks. The beta is 2.01, so 10x Genomics's price volatility has been higher than the market average.

Beta 2.01
52-Week Price Change -73.96%
50-Day Moving Average 10.22
200-Day Moving Average 15.87
Relative Strength Index (RSI) 36.77
Average Volume (20 Days) 3.74M

Income Statement

In the last 12 months, 10x Genomics had revenue of 610.78M and earned -182.63M in profits. Earnings per share was -1.52.

Revenue 610.78M
Gross Profit 414.48M
Operating Income -194.56M
Net Income -182.63M
EBITDA -133.99M
EBIT -177.7M
Earnings Per Share (EPS) -1.52
Full Income Statement

Balance Sheet

The company has 344.07M in cash and 82.61M in debt, giving a net cash position of 261.45M.

Cash & Cash Equivalents 344.07M
Total Debt 82.61M
Net Cash 261.45M
Retained Earnings -1.47B
Total Assets 918.64M
Working Capital 466.75M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 6.66M and capital expenditures -12.39M, giving a free cash flow of -5.73M.

Operating Cash Flow 6.66M
Capital Expenditures -12.39M
Free Cash Flow -5.73M
FCF Per Share -0.05
Full Cash Flow Statement

Margins

Gross margin is 67.86%, with operating and profit margins of -31.85% and -29.9%.

Gross Margin 67.86%
Operating Margin -31.85%
Pretax Margin -29.09%
Profit Margin -29.9%
EBITDA Margin -21.94%
EBIT Margin -31.85%
FCF Margin -0.94%

Dividends & Yields

TXG does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for TXG is $18, which is 138.7% higher than the current price. The consensus rating is "Hold".

Price Target $18
Price Target Difference 138.7%
Analyst Consensus Hold
Analyst Count 16
Stock Forecasts

Stock Splits

The last stock split was on Jul 17, 2006. It was a backward split with a ratio of 1:2.

Last Split Date Jul 17, 2006
Split Type backward
Split Ratio 1:2

Scores

Altman Z-Score 1.31
Piotroski F-Score 6